deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT01325441

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sponsor: Sumitomo Pharma America, Inc.

Conditions Cancer
Updated 21 times since 2017 Last updated: Nov 13, 2023 Started: Apr 30, 2011 Primary completion: Jun 1, 2021 Completion: Jun 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01325441, this PHASE1/PHASE2 trial focuses on Cancer and remains completed. Sponsored by Sumitomo Pharma America, Inc., it has been updated 21 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

This is an open label, multi-center, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced solid tumors for whom weekly paclitaxel is an acceptable option.

This is an open label, multi-center, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced solid tumors for whom weekly paclitaxel is an acceptable option.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 19 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

21 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  4. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Nov 2023 — Dec 2023 [monthly]

    Completed PHASE1_PHASE2

Show 16 earlier versions
  1. Mar 2023 — Nov 2023 [monthly]

    Completed PHASE1_PHASE2

  2. May 2022 — Mar 2023 [monthly]

    Completed PHASE1_PHASE2

  3. Sep 2021 — May 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not RecruitingCompleted

  4. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

  8. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .